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Abstract 
Mesenchymal stem cells ( MSCs) from umbilical cord stroma were isolated by plastic adherence and characterized by 
flow cytometry, looking for cells positive for OCT3/4 and SSEA-4 as well as the classic MSC markers CD44, CD73, 
CD90, Ki67, CD105, and CD106 and negative for CD34 and CD45. Quantitative reverse transcriptase–polymerase 
chain reaction analysis of the genes ALP, MEF2C, MyoD, LPL, FAB4, and AMP, characteristic for the differentiated 
lineages, were used to evaluate early and late differentiation of 3 germ lines. Direct chondrogenic differentiation was 
achieved through spheroid formation by MSCs in a chondrogenic medium and the presence of chondrogenic markers 
at 4, 7, 14, 28, and 46 days of culture was tested. Immunohistochemistry and quantitative reverse transcriptase–
polymerase chain reaction analyses were utilized to assess the expression of collagen type I, collagen type II, and 
collagen type X throughout the time studied. We found expression of all the markers as early as 4 days of 
chondrogenic differentiation culture, with their expression increasing with time, except for collagen type I, which 
decreased in expression in the formed spheroids after 4 days of differentiation. The signaling role of Wnt during 
chondrogenic differentiation was studied by western blot. We observed that β-catenin expression decreased during 
the chondrogenic process. Further, a secretome study to validate our model of differentiation in vitro was performed 
on spheroids formed during the chondrogenesis process. Our results indicate the multipotential capacity of this source 
of human cells; their chondrogenic capacity could be useful for future cell therapy in articular diseases. 
Mesenchymal stem cells (MSCs) were first identified in bone marrow [1] and characterized as a 
population of nonhematopoietic multipotent stem cells. Similar to other stem cell types, MSCs possess 
the potential for self-renewal and differentiation into highly specialized cells upon appropriate 
stimulation. Over the last decade, a number of studies have demonstrated that MSCs generate mature cell 
types, which typically arise from the endoderm [2] and ectoderm [3]. MSCs have been found in the 
majority of mature tissues, including skeletal muscle, pancreas, adipose tissue, and placenta [4]. Intensive 
research efforts in recent years have attempted to find alternative sources for MSCs. Several authors have 
characterized different MSC-like subpopulations in cultures obtained from Wharton’s Jelly, the mucoid 
connective tissue of the umbilical cord (UC); these subpopulations were shown to have the ability to 
differentiate toward multiple lineages, including adipose, bone, and neuronal lineages [5,6]. Expanding on 
this research, the human UC has gained attention as a source for MSCs. This postnatal organ has been 
found to be rich in stem cells, which, during growth, show characteristics typical of bone-marrow MSCs, 
such as plastic-adherent cells with a fibroblastic morphology, expression of a set of typical surface 
markers, and direct differentiation along mesodermal lineages. Compared with the bone marrow, UC 
tissues contain more stem cells with a higher in vitro expansion potential. Further, immune- privileged 
and immune-modulatory properties have been reported for UC-derived cells, which affords highly 
interesting approaches applicable for clinical use [7]. Importantly, because the UC is discarded after birth 
and the cells are easily accessible, the UC is a noncontroversial and noninvasive source of MSCs [8]. 
The Wnt family of signaling molecules is involved in chondrogenesis. Wnt proteins are distinguished 
by their capability to activate β-catenin into canonical Wnts (ie, Wnt3a) and noncanonical Wnts (ie, 
Wnt5a). The influence of Wnts on chondrogenesis is 2-fold and time dependent: at low levels Wnts 
promote chondroprogenitor differentiation, specifically through modulating Sox9 expression, and later at 
high levels they promote chondrocyte hypertrophy and subsequent endochondral ossification [9,10]. The 
regulation of chondrogenesis by Wnt signaling may depend on the environment of the cell or stage of 
differentiation [11]. Based on the role of Wnt signaling in cartilage development, it is not surprising that 
evidence indicating the involvement of Wnt signaling in the regulation of differentiated chondrocyte 
functions and cartilage disease is increasing. Although our current knowledge of the role of Wnt signaling 
in cartilage tissue is limited, a variety of Wnt signaling components may also regulate maintenance and 
destruction of cartilage tissue [12]. One challenge for the future is gaining a full understanding of the role 
of the Wnt signaling network in the maintenance of cartilage tissue and pathogenesis of joint disease. 
Lee et al. [13] performed a comparative proteome analysis of mesenchymal cells and chondrocytes to 
identify proteins differentially expressed during chondrogenesis. We used a proteomic strategy to study 
the secretome—proteins secreted into the medium during the differentiation process—of MSCs from UC 
stroma during their differentiation toward chondrocyte-like cells. Our previous work with a new model of 
chondrogenesis in vitro used to differentiate MSCs from synovium membrane [14] revealed high 
expression of collagen type II (COL2) by immunochemistry analysis and high amount of mRNA COL2 
gene as early as 14 days in culture, demonstrating that it could be a good chondrogenesis model. 
Materials and Methods 
Tissue collection 
Human UCs were obtained from cesarean sections performed on 23 healthy women in the Maternity 
Facility at Complejo Hospitalario Universitario A Coruña under the supervision of the hospital ethics 
committee. All tissues were obtained with fully informed consent and ethical approval by the supervisor 
of the Ethical Committee (CEIC) of Galicia. All women were between 26 and 35 years old. 
Isolation and culture of MSCs 
MSCs were isolated from UC stromal tissue by using a modification of the protocol developed by 
Messina et al. [15]. Briefly, the  tissue  was  washed with  phosphate-buffered saline (PBS) and cut in 
small pieces named explants, which were then incubated for three 5-min periods in an enzymatic cocktail 
containing 1.2 U/mL dispase and 112 U/mL type I collagenase (all from Sigma-Aldrich). The explants 
were cultured in Dulbecco’s modified Eagle’s medium (DMEM) with 10% fetal bovine serum, 1% 
penicillin, and 1% strep- tomycin (all from Sigma-Aldrich) and they adhered to the plastic plate. After 3 
days, the explants were removed from the plate, leaving attached UC MSCs, which were cultured in 
monolayer in the same medium. When the cells reached 90% confluence, they were removed from the 
plate by using 2% trypsin (Sigma-Aldrich) in PBS and they were induced to differentiate toward 
mesodermal or ectodermal germinal lines.  
Chondrogenic differentiation  
MSCs at P1 were seeded into 96-well plates (Sarstedt) at 2x10
4
 cells per well in DMEM with 10% 
fetal bovine serum, 1% penicillin, 1% streptomycin, 1.5x10
-4
 M monothioglycerol, 5mg/mL ascorbic 
acid, and 6 mg/mL transferrin (all from Sigma-Aldrich) to facilitate spontaneous spheroid formation. 
Following this step, the medium was changed to chondrogenic medium composed of DMEM with 15% 
knockout serum (Gibco, Invitrogen), 5mg/mL ascorbic acid, 6 mg/mL transferrin, 10 mM 
dexamethasone, 1x10
-7
 M retinoic acid, and 1 ng/mL recombinant human transforming growth factor-β3 
(TGF-β3) (ProSpec-Tany TechnoGene; Deltaclon). This medium was changed every 3 days. After 4, 7, 
14, 28, and 46 days in the chondrogenic medium, the spheroids formed were collected, frozen, and stored 
at -80ºC for posterior analyses. Control spheroids were grown under the same conditions, but in DMEM 
with 10% knockout serum (Gibco, Invitrogen), 1% penicillin, and 1% streptomycin (Sigma-Aldrich).  
Adipogenic and osteogenic differentiation 
MSCs at P1 were seeded in 96-well plates (Sarstedt) at 2x10
4
 cells per well in adipogenic or 
osteogenic commercial medium (Cambrex, Lonza), following the manufacturer’s instructions, to assess 
the mesodermal differentiation potential. The adipogenic cultures were stained with Oil Red O after 21 
days in culture. Briefly, the culture plates were fixed in 10 mM sodium periodate, 2% paraformaldehyde, 
75 mM L-lysine dihydrochloride, and 37.5 mM dibasic sodium phosphate (all from Sigma-Aldrich) at pH 
7.4 for 15 min at room temperature, then air dried, and stained with a filtered solution of 0.3% Oil Red O 
to reveal lipid droplets. The osteogenic cultures were stained with Alizarin Red to assess calcium deposits 
after 21 days in culture. After fixation, cells were covered with Alizarin Red S 2% aqueous solution at pH 
4.2 (Sigma-Aldrich) for 3 min. The cultures were then washed thoroughly with distilled water. 
Neuronal and myogenic differentiation 
Directed myogenic differentiation was performed following the method of Roura et al. [16], with 
some modifications. Briefly, cells were seeded in 96-well plates (Sarstedt) at 2x10
4
 cells per well in 
DMEM with 10% knockout serum, 1% penicillin, 1% streptomycin, 0.1 mM β-mercaptoethanol, and 40 
ng/mL fibroblast growth factor; this medium was changed every 3 days. After 21 days in culture, the cells 
were fixed with 4% paraformaldehyde in PBS and immunostained with a monoclonal antibody against 
human myosin (1:20; Alexis Biochemical, Enzo Life Sciences AG). Neural differentiation was induced 
using the method of Kang et al. [17], with some modifications. The cells were seeded in 96-well plates 
(Sarstedt) at 2x10
4
 cells per well in DMEM with 10% knockout serum (Gibco, Invitrogen), 1% penicillin, 
1% streptomycin, and 3 µL/mL of 5-azacytidine (Sigma-Aldrich). After 21 days in culture, the cells were 
fixed using 4% paraformaldehyde in PBS and immunostained with an anti- C-cadherin monoclonal 
antibody (1:25; Santa Cruz Biotechnology). Control spheroids were formed in the same way, culturing 
the cells in DMEM with 10% knockout serum (Gibco, Invitrogen), 1% penicillin, and 1% streptomycin, 
without further additives. 
FACS analysis 
Cells were fixed in 4% paraformaldehyde in PBS. After fixation, the cells were washed twice with 
PBS, permeabilized with PBS containing 0.1% Triton X-100 (Sigma-Aldrich) for 10 min, and then 
preblocked with 3% bovine serum albumin (BSA), or 2%–5% serum from the same species, in PBS. The 
following direct antibodies were used: phycoerythrin (PE) mouse anti-human CD34 (1:20; 
DakoCytomation); fluorescein isotiocyanate (FITC) mouse anti-rat CD44 (1:20; BD Pharmingen); FITC 
mouse anti-rat CD45 (1:20; BD Pharmingen); FITC mouse anti-human CD105 (1:100; Serotec); 
phycoerythrin Cy5.5 (PE-Cy5.5) mouse anti-human CD106 (1:20; Serotec); PE-Cy5.5-conjugated mouse 
anti-human CD90 (1:20; BD Pharmingen); PE-conjugated anti-human CD73 (1:20; BD Pharmingen); PE-
conjugated mouse anti-human CD166 (1:20; BD Pharmingen); R-PE mouse anti-human CD29 (1:100; 
BD Pharmingen), and  the following  primary antibodies were used: mouse anti-human Ki67 (1:20; Santa 
Cruz Biotechnology); mouse anti CD271 (1:20; Sigma-Aldrich); mouse anti-human CD117 (1:20; 
Serotec); Oct3/4 (Chemicon Inter- national, Millipore Iberica). For detection of primary anti- bodies not 
directly labeled, the cells were washed with PBS and then incubated with polyclonal rabbit anti-mouse 
IgD/PE Rabbit F(ab’)2 (1:1,000; DakoCytomation) for 30 min at room temperature. The stained cells 
were then washed twice with PBS and 10x105 cells were analyzed with a FACSAria flow cytometer (BD 
Bioscience). FACS data were generated by DIVA software (BD Bioscience). Negative control staining 
was performed using FITC-conjugated mouse IgG1k isotype, PE- conjugated mouse IgG1k isotype, and 
PE-Cy5.5-conjugated mouse IgG1k isotype (all from BD Pharmingen). 
  
RNA extraction and cDNA synthesis 
Total RNA was extracted from cells in culture using the Trizol L.S. reagent method (Invitrogen). 
Reverse transcription (RT) was carried out using the Superscript II system (Invitrogen). Total RNA (2 µg) 
was reverse transcribed in a 20 mL reaction volume containing Superscript II (200 units), random primers 
(25 µM), and dNTP (0.5 mM each) at 42ºC for 50 min. 
Real-time polymerase chain reaction analysis 
The reported sequences of genes for human SOX9, Nanog, Oct3/4, Sox2, MEF2C, MyoD, LPL, FAB4, 
AMP, ALP, OC, Runx2, and β-Actin were used for primer design. SOX9 were used to check the 
expression of the gene involved in early chondrogenesis stage. Nanog and Sox2 were used to check the 
expression of genes involved in no-differentiation stages. Genes for human MEF2C were employed to 
check for early neuronal differentiation, MyoD for myogenic differentiation, LPL, FAB4, and AMP for 
early and late adipogenic differentiation, and ALP, OC, and Runx2 to check early and late osteogenic 
differentiation. Details were shown in Table 1. The amplification program consisted of an initial 
denaturation at 92ºC for 2 min, followed by 40 cycles at 92ºC for 15 s, annealing at 61ºC for 30 s, and an 
extension at 72ºC for 15 s. Each polymerase chain reaction (PCR) analysis was done in duplicate, with 
each set of assays repeated 3 times. To minimize the effects of unequal quantities of starting RNA and to 
eliminate potential sources of inconsistency, the relative expression levels of each gene were normalized 
to β-actin using the 2-ΔΔCt method [18]. Control experiments did not include RT. 
Table 1. Specific primers for real-time reverse transcriptase–polymerase chain reaction amplification, listed with their annealing 
temperature 
Gene name Fw primer Rv primer mRNA ID AT (ºC) 
SOX9 gtacccgcacttgcacaac tcgctctcgttcagaagtctc NM_000346 61 
NANOG atgcctcacacggagactgt aagtgggttgtttgcctttg NM_024865 61 
RUNX2 gtgcctaggcgcatttca tgactggcggcgtgcaag NM_001024630 61 
COMP atggggaggaggttcttcag gaagaaccgagggtcgtct Q9NZP8  (Swissprot) 61 
MEF2C tgatcagcaggcaaagattg ggacactgggatggagactg NM_002397,2 61 
MyoD cactacagcggcgactcc taggcgccttcgtagcag P09871 (Swissprot) 61 
FABP4 ggatgataaactggtggtgga cacagaatgttgtagagttcaatc NM_001442 61 
APM1 ggtgagaaaggagatccaggt tgctgagcggtatacataggc NM_004797 61 
LPL agaacatcccattcactctgc ccatttgagcttcaacatgagt NM_000237 61 
COL1 gtgatgctggtcctgttggt caccatcgtgagccttctct NM_000088 61 
COL2 gtgtcagggccaggatgt tcccagtgtcacagacacagat NM_001844 61 
COL10 caccttctgcactgctcatc ggcagcatattctcagatgga NM_000493 61 
SOX2 ctccgggacatgatcagc ggtagtgctgggacatgtgaa NM_003106 61 
Oct3/4 ctcctggagggccaggaatc atatacacaggccgatgtgg DQ486513 61 
β-ACTIN agagctacgagctgcctgac ggatgccacaggactcca NM_001101 61 
     
 
Fw, forward; Rv, reverse; AT, annealing temperature 
Histological, immunofluorescence, and immunohistochemical analyses 
UC tissues were frozen at -80ºC until their immunoflu orescence analysis. Full-depth sections (4 mm) 
were cut using a cryostat and fixed in 4% (w/v) paraformaldehyde (Sigma-Aldrich) in PBS at pH 7.6. 
Immunofluorescence was performed by permeabilizing some sections with PBS containing 0.1% Triton 
X-100 for 10 min and then preblocking with 3% BSA or 2%–5% serum from the same species in PBS. 
The direct antibodies used were FITC mouse anti-rat CD44 (1:20; BD Pharmingen) or PE-Cy5.5–
conjugated mouse anti-human CD90 (1:20; BD Pharmingen); 40 ,6-diamidino-2-phenylindole was used 
to counterstain the nucleus. 
Spheroids from UC-MSCs, following differentiation into chondrocyte-like cells, neuronal-like cells, 
and myogenic-like cells, were frozen in OCT embedding matrix (BDH Chemicals). Full-depth sections (4 
mm) were cut using a cryostat and fixed in 4% (w/v) paraformaldehyde (Sigma-Aldrich) in PBS at pH 
7.6. Some sections were stained with hematoxylin and eosin, Safranin O, or Alizarin Blue (all from 
Sigma-Aldrich) to evaluate the distribution of matrix, proteoglycan, and polysaccharides, respectively. 
Other sections were immunostained with monoclonal antibodies against COL1 (1:1,000), COL2 (1:50), 
and COL10 (1:2,000) (all from Southern Biotechnologies) and used as previously described by Arufe et 
al. [14]. Biotinylated secondary antibodies were detected using a peroxidase-labeled biotin–streptavidin 
complex  (Vectastain  Elite kit; Vector  Laboratories) with diaminobenzidine substrate (Vector 
Laboratories) (1:1,000). Human cartilage and skin were used as positive controls for detection of COL2, 
aggrecan, and COL1, respectively (data not shown). Normal mouse serum was used as a negative control, 
and the sections were not counterstained. 
Densitometry analysis 
AnalySIS Image Processing was used to quantify the expression of antibodies obtained by the 
immunohistochemical analyses of sections of the spheroids. Three 200-µm
2
 fields were quantified for 
each antibody; immunohistochemistry values in arbitrary units were assigned by the computer program. 
The values were expressed as the percentage of positive cells for each marker studied for 
immunohistochemistry analysis. All values were referenced to values obtained from stained sections of 
control spheroids cultured in DMEM. Control values for chondrogenesis were obtained using spheroids 
incubated only with secondary antibody during the immunohistochemistry analysis. 
Protein isolation and immunoblot analysis 
Immunoblot analysis was performed on 40 µg of total protein extracted from cells in culture, as 
previously described [19]. The blots were probed with antibodies directed against human β-catenin and 
glycerol-3-phosphate dehydrogenase (both from Sigma-Aldrich). A secondary anti-mouse antibody 
(Santa Cruz Biotechnology) was used to visualize proteins by using an Amersham™ ECL™ Western 
Blotting Analysis System (GE Healthcare, Amersham Biotechnology). Ideal concentrations for each 
antibody were empirically determined. Working concentrations were 1:1,000 of the recommended stock 
solutions. 
Secretome study 
Spheroids at 4, 7, 14, 28, and 46 days of chondrogenesis differentiation were washed in PBS and 
transferred to a well with only  RPMI for 12 h. Proteins  secreted  from  those spheroids into the medium 
were recovered, avoiding serum contamination. 
The medium containing the secreted proteins was filtered and concentrated using 10 kDa MWCO 
Amicon columns (Sigma-Aldrich). The concentrated medium (40 µL) was mixed with Laemmli protein 
loading buffer, and sodium dodecyl sulfate–polyacrylamide gel electrophoresis (SDS- PAGE) was 
performed using precast NuPAGE® NOVEX gels (Invitrogen) to ensure reproducibility in the separation 
of the proteins. The gels were stained with silver nitrate and the entire lane was divided into 16 sections 
(Fig. 7A). Each section was excised and in-gel digestion with trypsin was carried out following standard 
procedures. Each peptide mixture was cleaned and desalted with Poros R2 columns, injected using a 
trapping-column, and separated using a nanoLC system (Tempo; Eksigent, Applied Biosystems) in a C18 
silica-based column with 300 Ǻ internal diameter (New Objective). Peptides eluted during a 50 min 
gradient up to 40% acetonitrile were mixed with α-cyano and deposited on a MALDI plate using an 
automatic MALDI spotter (Applied Biosystems). The mass spectrometry run for each fraction was 
analyzed in an ABI 4800 MALDI-TOF/TOF (Applied Biosystems) instrument and fragmentation—
MS=MS—was done using a CID system (Applied Biosystems). Database searching was accomplished 
using ProteinPilot (Applied Biosystems) as the search engine for the latest SwissProt release (SP release 
57.10, November 2009), with 512,205 entries. Only proteins with at least one specific (unused score = 
total score) human peptide identified with >99% confidence were considered for inclusion in the final list. 
  
Statistics 
All experiments were done in triplicate and a representative result  is shown. Statistical analyses were 
performed using the Student’s t-test and analysis of variance using SPSS 16.0. P < 0.05 was considered 
statistically significant. 
Results 
The expression of the MSC markers CD44 and CD90 was ascertained using immunofluorescence in 
cryosections of UC tissue, as shown in Fig. 1. Higher concentrations of CD44- and CD90-positive cells 
were found in the stroma (Fig. 1C, D) of the UC than in the regions around veins (Fig. 1A, B) or arteries 
(Fig. 1E, F). The colocalization of both antibodies occurred in the same cell (Fig. 1D). 
 
 
 
FIG. 1. Detection of the mesenchymal stem cell (MSC) markers, CD44 and CD90, in umbilical 
cord tissue using immunofluorescence in 7-µm- thick cryosections. (A, B) Negative control. 
Region surrounding a vein stained with 40 ,6-diamidino-2-phenylindole. (A, 10x; B, 20x). (C, D) 
Detection of CD44 and CD90 in a region of Wharton’s Jelly. (C, 10x; D, 20x). (E, F) Detection 
of CD44 and CD90 in a region surrounding an artery (E, 10x; F, 40x). 
Characterization of cells 
Characterization of MSC populations isolated from UCs was made using flow cytometry analysis 
before differentiation studies to determine their multipotency (Fig. 2A). A high percentage of MSCs were 
positive for CD90 (>40%), whereas a lower percentage of cells were positive for CD44 (27%), CD105 
(10%), and CD29 (9%). The remaining tested markers had <10% positive cells, with CD34 and CD45 
<1% positive, essentially negative for those markers (Fig. 2A). 
The multipotency of the MSC population before differentiation was also tested by real-time RT-PCR 
for expression of the genes SOX9, Nanog, Oct3/4, and SOX2 (Fig. 2B). All measurements were 
compared with the gene expression of OCT3/4 in the MSC pool, because this gene had the lowest level of 
expression. 
 
 
 
FIG. 2. Characterization of MSCs from umbilical cord stroma. (A) Characterization of MSCs from umbilical cord stroma using 
flow cytometry. The MSC markers are indicated at the top of each plot, the fluorochrome used is indicated at the bottom of the plot, 
and the percentage of positive cells for each marker is given in Table 1. (B) Characterization of MSCs by quantitative reverse 
transcriptase–polymerase chain reaction (RT-PCR). The percentage of gene expression is indicated on the y-axis and the genes are 
named on the x-axis. The expression of each gene was normalized to that of Oct3/4. FITC-A, fluorescein isotiocyanate A; PE, 
phycoerythrin; PerCP-Cy5, phycoerythrin Cy5.5 
Multipotential capacity of MSCs 
After 21 days of osteogenesis differentiation, as described earlier, almost 100% of the cells seeded in 
the wells were positive for Alizarin Red stain (Fig. 3A). The genes OC and Runx2, which are involved in 
osteogenesis, were highly expressed, achieving levels of 10,000-fold more than the expression of the 
same genes in the DMEM-cultured control cells (Fig. 3B). 
After 21 days of adipogenesis differentiation, as described earlier, almost 100% of the seeded cells 
were positive for Oil Red O stain (Fig. 3A) and the expression of the LPL, FAB4, and  AMP genes 
related  to adipogenesis were very high, having levels of 1,000-fold more than the expression of the same 
genes in the control cells (Fig. 3B). 
Following ectodermal differentiation in medium with 5- azacitidyne for 21 days, as described earlier, 
90% of the cells seeded in the well were positive for C-cadherin human antibody (Fig. 3A). MEF2C gene 
expression related to neuronal differentiation was elevated 10-fold above the expression of the same gene 
in control cells (Fig. 3B). 
Subsequent to myogenesis differentiation in medium with β-mercaptoethanol for 21 days, 90% of the 
cells were positive for Myo D human antibody (Fig. 3A). Myo D gene expression, which is related to 
myogenesis, was 10-fold more than the expression of this gene in the controls (Fig. 3B). 
 
 
 
FIG. 3. Differentiation of MSCs along mesodermal and ectodermal lineages. (A) MSCs from 
umbilical cord stroma were differentiated toward osteocytes (top panel) and adipocytes (middle 
upper panel), using commercial media (Cambrex). Some MSCs were also differentiated toward 
neuronal cells (middle lower panel) using DMEM with 5-azacytidine and other MSCs 
differentiated toward myocytes (lower panel) using DMEM supplemented with β-
mercaptoethanol. The cells were cultured for 21 days. Oil Red O and Alizarin Red were used to 
stain for adipocytes and osteoblasts, respectively. Immunohistochemistry to detect C-cadherin 
and MyoD were used to verify neurogenesis and myogenesis, respectively (magnification: 10x). 
(B) Quantitative RT-PCR testing for expression of genes involved in the mesodermal and 
ectodermal differentiation process. ALP, OC, and Runx2 (top panel) were significantly (P = 
0.05) increased in MSCs cultured for 21 days in osteogenic differentiation medium compared 
with control MSCs cultured in DMEM. LPL, FAB4, and AMP (middle upper panel) were 
significantly (P = 0.05) expressed in MSCs differentiated for 21 days in adipogenic medium 
compared with controls. The expressions of MEF2C (middle lower panel) and MyoD (lower 
panel) were significantly increased (P = 0.05) in MSCs differentiated for 21 days in specific 
differentiation media, compared with control cells. OM, commercial medium for osteocytes; 
AM, commercial medium for adipocytes; 5-Az, DMEM plus 5-azacytidine; B-M, DMEM with 
b-mercaptoethanol; DMEM, Dulbecco’s modified Eagle’s medium. *P < 0.05 by the Student’s t-
test 
Chondrogenesis study 
The chondrogenesis study focused on the expression of COL2 and Col1 using immunohistochemistry 
of sections of spheroids (Fig. 4A, B). Hypertrophy in this particular chondrogenic model was also 
assessed by immunohistochemistry for COL10 (Fig. 4A, B). Densitometry, using AnalySIS Image 
Processing, quantified the expression of antibodies obtained using immunohistochemistry (Fig. 4C). The 
values derived from the control spheroids (Fig. 4A) were used as controls for the densitometry studies 
(Fig. 4C, D). Specifically, the MSC subpopulation showed a decrease in COL1 staining with time, with a 
significant (P < 0.05) decrease after 14 days in chondrogenic medium; this level of COL1 staining was 
maintained after 14 days in culture. Staining for COL2 was present in the MSC population cultured in 
chondrogenic medium at all times points, increasing in intensity to reach peak staining at 28 and 46 days; 
these levels differed significantly (P < 0.05) from the other times studied. During chondrogenesis, 
staining for COL10 was maintained at the same level throughout (4–46 days), with no significant 
differences in its expression (Fig. 4B). The ratio of COL2/COL1 shown in Fig. 4D portrays the 
chondrogenic process. From day 14 to 46, an increase in the COL2=COL1 ratio was observed during the 
differentiation process, with the difference being significant (P < 0.05) be- tween day 14 and days 24 and 
46 of differentiation. 
 
 
 
FIG. 4. Analysis of chondrogenesis in spheroids engineered using MSCs derived from umbilical 
cord stroma after 4, 7, 14, 28, and 46 days in culture in chondrogenic differentiation media. (A) 
Immunohistochemistry analysis of control spheroids engineered from MSCs isolated from 
umbilical cord stroma after culture in control medium (DMEM, 10% knockout serum, 1% 
penicillin, and 1% streptomycin). (B) Immunohistochemistry analysis of spheroids engineered 
from MSCs of umbilical cord stroma after culture using a specific chondrogenic differentiation 
media (DMEM, 15% knockout serum, 5 mg/mL ascorbic acid, 6 µg=mL transferrin, 10 µM 
dexamethasone, 1x10-7 M retinoic acid, and 1 ng/mL recombinant human transforming growth 
factor-β3). (C) Plot representing arbitrary densitometry units for the expression of antibodies for 
collagen type I (COL1), collagen type II (COL2), and collagen type X (COL10). (D) Plot 
representing the densitometry study of the ratios of expression of the antibodies for COL1 and 
COL2 from day 4 to day 46 in culture. (E) Safranin O staining of spheroids engineered from 
MSCs of umbilical cord stroma after 46 days in culture using a specific chondrogenic 
differentiation media (on the right) and DMEM (on the left). All figures were at 20x 
magnification. (C, D) The AnalySIS Image Processing computer program was used to quantify 
the expression of different antibodies obtained by immunohistochemical analysis. The y-axis 
shows the mean normalized signal of triplicate spheroids at 4, 7, 14, 28, and 46 days of 
differentiation in chondrogenic medium. Similar results were obtained from 3 independent 
experiments. *P < 0.05 by the Student’s t-test. 
  
The analysis of chondrogenesis by quantitative RT-PCR of gene expression of COL1, COL2, and 
COL10 is shown in Fig. 5A. There was a significant  increase in COL1, COL2, and COL10 expression 
after 4 days  in chondrogenic medium compared with day 0 (undifferentiated) (P < 0.05). After 7 days in 
chondrogenic culture, only COL1 expression showed a significant decrease from day 4 (P < 0.05). 
Significant increases of the expression of COL2 and COL10 were observed at days 28 and 46 compared 
with previous days (P < 0.05). 
 
 
 
FIG. 5. Expression of mRNA during chondrocyte-like cell 
differentiation in spheroids engineered using MSCs derived 
from umbilical cord stroma after 4, 7, 14, 28, and 46 days in 
culture in chondrogenic differentiation medium. Seven 
spheroids were isolated for nested quantitative RT-PCR. No 
signal was observed without reverse transcription or when the 
first 21 cycles were carried out with a primer set for a 
different gene, indicating that the positive signals originated 
from the corresponding transcripts. Essentially the same 
results were obtained from 3 independent experiments. The 
graph shows the quantification of COL1, COL2, and COL10 
mRNA expression, using the software Image Quant 5.0 for 
PC. The y-axis shows the mean normalized signal of 
triplicate spheroids at 0, 4, 7, 14, 28, and 46 days in 
chondrogenic differentiation media. *P < 0.05 by  the  
Student’s t-test. β-Actin was used as housekeeping gene 
Wnt pathway during chondrogenesis 
During chondrogenesis, the differential expression of the main protein of the Wnt signaling pathway, 
β-catenin, was performed using western blots (Fig. 6). The results revealed that β-catenin expression 
decreased during chondrogenic differentiation. This decrease was significant between days 4 and 7 (P < 
0.05) and between days 7 and 14 (P < 0.05) in chondrogenic medium. 
  
 
 
 
FIG. 6. Wnt signaling during chondrocyte-like cell differentiation in spheroids 
engineered using MSCs derived from umbilical cord stroma after 4, 7, 14, 28, 
and 46 days in culture in chondrogenic differentiation media. (A) Western blot 
detection of β- catenin from the total protein of spheroids formed from MSCs 
before differentiation (MSC) and from chondrocytes obtained from normal 
human cartilage used as a positive control (Ch.). (B) The AnalySIS Image 
Processing pro- gram was used to quantify the expression of β-catenin and 
GAPDH obtained by western blot. The y-axis shows the mean normalized 
signal of triplicate spheroids at 4, 7, 14, 28, and 46 days in chondrogenic 
differentiation medium. Essentially similar same results were obtained from 3 
independent experiments. *P < 0.05 by the Student’s t-test 
Secretome study during chondrogenesis 
Secretome analysis using one-dimensional (1D) SDS-PAGE coupled to nanoLC MALDI_TOF/TOF 
identified a total of 342 proteins at different time points of chondrogenesis by MSCs from human UC 
stroma. To assess serum contamination from previous media incubations in this study, media collected at 
1 h after introducing the spheroid into the well (day 0) was included in this analysis. Only BSA and 
vimentin were identified at day 0 (data not shown), both with low scores, showing that exhaustive 
spheroid washing avoids serum contamination. 
Two hundred nine of the identified proteins were directly linked to extracellular processes and 133 
proteins were linked to other cellular processes relating to nuclear and cytoplasm compartments. The 
percentage of identified proteins involved in the chondrogenesis process constituted 17% of the total 
proteins detected at 4 days of chondrogenic differentiation; this value increased with further culture in 
chondrogenic medium: 57.5% at 7 days, 55.17% at 14 days, 62% at 28 days, and 64.9% at 46 days (Fig. 
7B). 
All of the proteins related to the chondrogenic differentiation process are included in Table 2: 
chitinase-3–like protein, which is a cartilage-specific protein, metalloproteinase inhibitors 1 and 2, which 
are collagenase inhibitors, fibronectin, which binds cell surfaces, and other proteins including collagen. 
They were detected at 4 days of differentiation and continued to be detectable throughout the 46 days of 
chondrogenesis, with one exception. Fibronectin, which is involved in cell adhesion, cell motility, 
opsonization, wound healing, and maintenance of cell shape, was not found at 46 days of differentiation. 
There were several other proteins detected in the secretome from the spheroids after 46 days in 
chondrogenic culture medium, including biglycan, a matrix constituent of the deep zone of cartilage, and 
stromelysin-1, which degrades fibronectin, laminin, gelatins of type I, III, IV, and V; collagens III, IV, X, 
and IX, and cartilage proteoglycans. 
All 342 identified proteins by this method were divided into metabolic process categories using the 
Pathway Studio 6.0 Software (Ariadne Genomics) and the results are shown in Fig. 7C. Only the 
percentage of those proteins related to chondrogenesis increased throughout the differentiation process, 
while the proteins related to cell organization initially increased, then decreased at 28 days of 
differentiation and increased again at 46 days. The remaining metabolic process categories involved in 
signal transduction, protein synthesis, proteolysis, metabolism, energy production and stress and redox 
process, essentially maintained the same percentage of proteins throughout the differentiation process. 
 
 
 
FIG. 7. Secretome analysis using one-dimensional sodium dodecyl sulfate–polyacrylamide gel 
electrophoresis coupled to nanoLC  MALDI-TOF/TOF of MSCs derived from umbilical cord 
stroma after 4, 7, 14, 28, and 46 days in culture in chondrogenic differentiation medium. (A) 
One-dimensional sodium dodecyl sulfate–polyacrylamide gel electrophoresis: the total secreted 
protein from spheroids formed at 4, 7, 14, 28, and 46 days of chondrogenic differentiation were 
separated and divided into 16 fractions for digestion with trypsin to enable later separation by 
nanoLC and identification by MALDI- TOF/TOF. (B) The percentage of secreted proteins 
involved in chondrogenesis is represented compared with the total secretome during the 
differentiation process. The numbers at the top of the plot indicate the total proteins identified. 
(C) The plot represents the percentages of the proteins from the total secretome that are involved 
in the principal metabolic pathways during the chondrogenic process. 
Discussion 
Human UC cord tissue is an excellent source for noncontroversial stem cells. Schugar et al. 
demonstrated in situ characterizations identifying and  localizing  a  panel  of markers expressed by 
MSCs, including CD44, CD105, CD73, and CD90 [6]. In our study, immunofluorescence analysis 
revealed that CD44 and CD90 were present within the same cell, and  that  these  cells possessing both  
markers were abundant in the stroma of the human UC (Fig. 1) and were maintained during in vitro 
culture (Fig. 2A). Our populations of MSCs isolated from UC stroma also possessed an abundance of 
MSC markers in their membranes [6]. 
  
Table 2. Secretome Analysis Using One-Dimensional Sodium Dodecyl Sulfate–Polyacrylamide  Gel Electrophoresis Coupled to 
NanoLC MALDI_TOF/TOF at Different Time Points of Chondrogenesis by Mesenchymal Stem  Cells from Human Umbilical 
Cord Stroma 
SwissProt 
accession no. 
Name 
ProteinPilot 
unusued score 
% Coverage 
    
Day 4    
P02751  Fibronectin  44.58 24.4 
P01033  Metalloproteinase inhibitor 1  19 64.3 
P16035  Metalloproteinase inhibitor 2  4 20 
Q15582  TGF-β–induced protein ig-h3  10 14.5 
P08253  72-kDa type IV collagenase  5.52 7.3 
P02452  Collagen alpha-1(I) chain  17.44 44.5 
P08123  Collagen alpha-2(I) chain  2.72 11.3 
P36222  Chitinase-3–like protein 1  2.66 22.2 
P09486  SPARC  2.14 9.6 
P07585  Decorin  2 10.6 
P27797  Calreticulin  2 4.3 
Day 7    
P02751  Fibronectin  36.39 23.4 
P01033  Metalloproteinase inhibitor 1  9.08 48.8 
Q15582  TGF-β–induced protein ig-h3  2 6.4 
P24821  Tenascin  13.65 13.9 
P13611  Versican core protein  34.12 15.2 
P08123  Collagen-alpha-2(I) chain  4.21 13.5 
P02452  Collagen alpha-1(I) chain  3.79 23.8 
P09382  Galectin-1  2.89 22.2 
P51884  Lumican  2.1 6.5 
P36222  Chitinase-3–like protein 1  2.03 15.1 
P02461  Collagen alpha-1(III) chain  2.02 15.3 
P03956  Intersticial collagenase  2 5.8 
P24821  Tenascin  13.65 13.9 
Day 14    
P36222  Chitinase-3–like protein 1  2.03 15.1 
P02751  Fibronectin  96.17 45.7 
P01033  Metalloproteinase inhibitor 1  2 20.6 
P13611  Versican core protein  34.12 15.2 
Q15582  TGF-β–induced protein ig-h3  16.92 38.8 
P98160  Basement membrane-specific heparin sulfate proteoglycan 11.39 18.4 
P08253  72-kDa type IV collagenase  7.37 25.3 
P07585  Decorin  6.59 25.1 
P08123  Collagen-alpha-2(I) chain  5.59 28.8 
P23142  Fibulin  4.13 14.9 
P09486  SPARC  2.03 16.2 
P51884  Lumican  2 9.2 
P12111  Collagen-alpha-3(VI) chain  2 4.8 
P24821  Tenascin  59.86 32.9 
Day 28    
P02751  Fibronectin  54.83 27.3 
P24821  Tenascin  54.52 28 
Q15582  TGF-β–induced protein ig-h3  33.1 45.4 
P07585  Decorin  16.5 33.4 
P08253  72-kDa type IV collagenase  12.08 33 
P02452  Collagen-alpha-1(I) chain  11.47 37.4 
P13611  Versican core protein  9.1 7.7 
P23142  Fibulin-1  6.4 15.1 
P01033  Metalloproteinase inhibitor 1  5.7 39.6 
P09486  SPARC  4.12 16.2 
P51884  Lumican  4 17.8 
Q15063  Periostin  2.57 17.9 
P36222  Chitinase-3–like protein 1 2.43 25.3 
P02461  Collagen alpha-1(III) chain  2 10.1 
Day 46    
P24821  Tenascin  84 36 
P02452  Collagen-alpha-1(I) chain  24.92 59.1 
P08253  72-kDa type IV collagenase  20 28.6 
P51884  Lumican  16.09 29.3 
P23142  Fibulin-1  15.25 20.8 
P03956  Intersticial collagenase  12.99 38.6 
Q99715  Collagen alpha-(XII) chain  11.26 11.5 
P08254  Stromelysin-1  10.03 24.9 
Q15582  TGF-β–induced protein ig-h3  10 15.52 
P36222  Chitinase-3–like protein 1  6.01 23.8 
P01033  Metalloproteinase inhibitor 1  6 20.08 
P14543  Nidogen-1  4.01 6.6 
P13611  Versican core protein  4.01 5.4 
P51884  Lumican  4.01 20.4 
P09382  Galectin-1  4.01 34.8 
P27797  Calreticulin  4 16.1 
P09486  SPARC  4 13.9 
P24593  Insulin-like growth factor-binding protein 5 4 16.9 
P16035  Metalloproteinase inhibitor 2  4 30.5 
Q12841  Follistatin-related protein 1  3.71 18.2 
P98160  Basement membrane-specific heparan sulfate proteoglycan 3.4 4.1 
Q15063  Periostin  2.48 14 
P21810  Biglycan  2 22 
Q07507  Dermatopontin  2 14.9 
    
 
Only those proteins involved in chondrogenesis from the UniProt web database and identified with at least one specific human 
peptide with confidence >99% were included in the list (unused score = total score = 2). 
The multipotency of MSCs from human UC stroma was confirmed by their ability to differentiate into 
different cell types such as neurons, myocytes, and adipocytes (Fig. 3). Robin et al. [20] found that 
perivascular cells purified from skeletal muscle and nonmuscle tissues were myogenic in culture and in 
vivo. Regardless of their tissue origin, long- term cultured perivascular cells retained myogenicity, 
exhibited osteogenic, chondrogenic, and adipogenic potential, expressed MSC markers, and migrated in a 
culture model of chemotaxis. The pluripotency of our MSCs was also examined through the expression of 
genes involved in the undifferentiated stage, such as Nanog, Oct3/4, and SOX2 (Fig. 2B). Bhattacharya et 
al. [21] indicated that these genes, previously identified as ‘‘stemness’’ genes in undifferentiated human 
embryonic stem cell lines, slowed down modulation in differentiated cells, whereas the expression of 
several other genes was induced during cell differentiation. We included SOX9 (Fig. 2B) as an 
undifferentiated gene because SOX9 is a transcription factor with a high-mobility group DNA-binding 
domain. SOX9 activates chondrocyte-specific marker genes such as COL2, COL1, and aggrecan and is 
expressed in all chondroprogenitors and chondrocytes, except for hypertrophic chondrocytes [22]. The 
expression of SOX9 indicates that our MSCs isolated from UC stroma had chondrogenic potential. 
Chondrogenic differentiation was achieved following the direct chondrogenic differentiation in vitro 
protocol developed by our group [14]. We measured the production of specific chondrogenic markers at 
4, 7, 14, 28, and 46 days of culture in chondrogenic medium. Immunohistochemistry and quantitative RT-
PCR analysis measured the expression of COL1, COL2, and COL10 in the spheroid formed during the 
chondrogenic process. Because spheroids first appear in our model after 2 days in culture in 
differentiation medium, the measurement of the expression of COL1, COL2, and COL10 in the spheroids 
was begun at 4 days. We found the expression of COL1, COL2, and COL10 in the spheroids as early as 4 
days of chondrogenic differentiation. COL2 and COL10 both increased their expression over time; the 
expression of COL1 decreased after 4 days of differentiation. Thus, the COL2/COL1 ratio increased over 
time (Fig. 4D), adding a more consistent assessment of our chondrogenic model. Our differentiation 
protocol has similarities to that of Johnstone et al., published in 1998, for the development of an in vitro 
cartilage  model  based on micromass culture [23]. 
Penolazi et al. [24] found that the osteoblastic potential of UC MSCs was not influenced by the baby’s 
gender or mode of delivery. However, the highest degree of osteoblastic potential has been shown by 
MSCs, with high basal levels of RUNX-2 isolated from UCs from the heaviest  full-term babies [24]. 
MSCs isolated from UCs represent a promising source for the repair of hard tissue such as 
cartilaginous tissues. Im et al. [25] tested the hypothesis that the inhibition of the Wnt pathway promotes 
chondrogenesis by human MSCs. They concluded that, for early chondrogenesis, both Dickkopf- related 
protein 1 and secreted frizzled-related protein 1 (sFRP-1) increased glycosaminoglycan synthesis, as well 
as the gene and protein expressions of SOX9 and COL2, more prominently by sFRP-1 than by Dickkopf-
related protein 1. However, after 21 days of in vitro chondrogenic culture with TGF-b3, sFRP-1 treatment 
did not further increase the gene expression of SOX9 and COL2. The overall results of this study suggest 
that, although the inhibitors of the Wnt pathway promote early chondrogenesis from MSCs, they do not 
ultimately enhance cartilage tissue engineering from MSCs. Our results indicate that β-catenin expression 
decreases during chondrogenic differentiation, adding new information about its role in mammalian cell 
chondrogenesis in concordance with Liu et al. [11]. They described that the inhibition of Wnt signaling 
was necessary during the early stages of mammalian chondrogenesis and described for the first time that 
β-catenin is found at low values in the cells during the chondrogenesis process. This finding adds a new 
role for Wnt signaling during the mammalian chondrogenesis process. 
Stem cells have been widely studied for their suitability for use in tissue repair therapies. However, 
differences in function and differentiation potential exist between distinct stem cell populations. Whether 
those differences are due to donor variation, cell culture, or an intrinsic property remains elusive. The 
existence of these differences, however, indicates a need for effective differentiation protocols tailored to 
each stem cell type [26]. 
Our in vitro chondrogenic model was also validated by mass spectrometry; we were able to identify 
typical cartilage proteins secreted during the differentiation process with the chondrogenic medium, but 
not with the DMEM, in which no expression of COL2 was seen in the spheroid. To our knowledge, this is 
the first time that 1D-SDS-PAGE coupled to nanoLC MALDI-TOF/TOF has been used to analyze the 
secretome of MSCs isolated from human UC cord stroma. This qualitative technique is suitable for 
analyzing complex samples such as secretomes. We found that the majority of proteins secreted during 
the differentiation process were involved in chondrogenesis. Chondrogenic differentiation resulting from 
spheroid formation is an excellent method for obtaining chondrocyte-like cells from MSCs derived from 
human UC stromal tissue. Some of these proteins at 4 days of differentiation culture include Decorin, 
which binds to COL1 and 2, fibronectin, and TGF-β, forms a ternary complex with microfibrillar-
associated protein 2 and elastin, and interacts with dermatopontin; and Calreticulin, which increases cell 
proliferation. Some of these proteins at 7 days of differentiation culture include Lumican, which is located 
in the extracellular matrix (ECM) of human articular cartilage at all ages, although its abundance is far 
greater in the adult; and Galectin-1, which regulates apoptosis, cell proliferation, and cell differentiation, 
binds β-galactoside and an array of complex carbohydrates, and inhibits CD45 protein phosphatase 
activity and, therefore, the dephosphorylation of Lyn kinase. At 14 days of differentiation we found 
Fibulin, which may play a role in cell adhesion and migration along protein fibers within the ECM and 
could be important in certain developmental processes as well as contribute to the supramolecular 
organization of ECM architecture, particularly to those of basement membranes; Decorin; and Lumican. 
Proteins seen at 28 days were Periostin, which induces cell attachment and spreading, plays a role in cell 
adhesion, and may play a role in ECM mineralization; Decorin; Lumican; and Chitinase. At 46 days we 
found Dermatopontin, which enhances TGF-β1 activity and inhibits cell proliferation, accelerates 
collagen fibril formation, and stabilizes collagen fibrils against low-temperature dissociation; and 
Nidogen-1, which is widely distributed in basement mem- branes and tightly associated with laminin, 
COL4, and perlecan. Nidogen-1 has a role in cell–ECM interactions. Several types of collagens were also 
found by MS, although we found no COL2, the one collagen specific to cartilage tissue. This could be 
because all the identified peptides are C- terminal peptides, which has very high homology among the 
different collagens. The N-terminal part of the protein is more specific for each collagen type, but 
identification of N-terminal peptides using MS is challenging because of inherent limitations of the 
technique. Through 1D-SDS-PAGE coupled to nanoLC MALDI-TOF/TOF used to analyze the secretome 
during the chondrogenic process, several glycos-aminoglycans were found, including fibronectin, which 
was present in the chondrogenic process from day 4 through 46, tenascin, present in the chondrogenic 
process from day 7 through 46, and basement membrane-specific heparan sulfate proteoglycan, present in 
the chondrogenic process from day 14 through 46. Chitinase-3–like protein 1, a cartilage- specific protein 
that was found in our model throughout differentiation time, demonstrated the efficacy of our model. 
Hayes et al. [27] described biglycan and decorin as matrix constituents of cartilage; their presence further 
corroborates our results. Our model of chondrogenesis is a dynamic model where we found proteins that 
degrade collagen, such as stromelysin-1, at the end of our differentiation culture. 
All these findings demonstrate that MSCs from UC stroma are multipotent cells able to differentiate 
into mesodermal and ectodermal lineages. The defined chondrogenic medium and the spheroid model are 
useful to obtain chondrocyte-like MSCs from the UC stroma. Various techniques, including immuno- 
histochemistry, RT-PCR, and 1D-SDS-PAGE coupled to nanoLC MALDI-TOF/TOF, yielded evidence 
of protein and gene expressions characteristic of native cartilage. 
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